Hengrui Medicine (600276): Novo license deal reinforces Goldman Sachs' positive view of Hengrui's next-generation obesity pipeline

Overview

This event-driven update examines Hengrui Medicine's license-out of oral GLP-1/GIP candidate HRS-1596 to Novo Nordisk. Goldman Sachs views the transaction as validation of Hengrui's broader obesity and metabolic-disease strategy, alongside its continuing transition toward innovative drugs and overseas commercialization partnerships.

Core views

Hengrui has granted Novo exclusive ex-China rights to HRS-1596, a Phase I-ready once-weekly oral GLP-1/GIP peptide for obesity and type 2 diabetes. The agreement provides US$300mn upfront, potential development, regulatory and commercial milestones of up to US$2.3bn, and royalties on future sales. HRS-1596 has received China IND approval, with China Phase I trials planned for 2026 and preliminary data expected in 2027. Goldman Sachs stresses that the asset remains very early stage, but interprets Novo's upfront payment as evidence of strategic interest in differentiated oral incretin therapies and as support for investor confidence in Hengrui's cardiometabolic pipeline. The report argues that the deal supports a broader obesity strategy rather than representing a standalone asset outcome. Hengrui entered GLP-1 later than global peers but has built a pipeline aimed at differentiation across efficacy, convenience and mechanism. Its key strategic asset HRS-9531, an oral GLP-1/GIP agonist, produced Phase II weight loss of 12.1% at week 26, or 9.8% placebo-adjusted, with a reported vomiting rate of 11.4%. Beyond GLP-1/GIP and other multi-target agonists intended to enhance efficacy, Hengrui is pursuing oral and long-acting formats to improve convenience, as well as INHBE- and amylin-based approaches intended to preserve muscle mass and broaden metabolic benefits. Goldman Sachs places the obesity opportunity within Hengrui's wider shift from a previous "generics + innovation" model toward innovative drugs. The company has launched nine products with sales above Rmb1bn in recent years, including four innovative drugs. The institution expects future growth to be driven by innovative assets including HER2 ADC, CDK4/6, AR antagonist, PI3Ki, obesity and autoimmune therapies, after the major impact of volume-based procurement price cuts was largely reflected and reset to a lower base in 2022. It also sees the Novo transaction as part of an increasingly diversified overseas business-development record extending beyond oncology. Goldman Sachs maintains a Buy rating and a 12-month Rmb73.86 target price, versus a Rmb45.62 closing price on 29 September 2026, implying 61.9% upside. Its valuation combines Rmb39.3bn for the generics business using a five-year exit P/E of 10x with Rmb390.7bn for innovative drugs using a risk-adjusted DCF based on a 9.0% WACC and 3% terminal growth rate. The institution's central view is that the prevailing valuation largely reflects Hengrui's China prospects, while further overseas progress could add upside.

Analysis framework

Goldman Sachs evaluates the Novo license transaction in the context of Hengrui's obesity pipeline, clinical differentiation and broader overseas business-development strategy. It supports the investment view with pipeline-stage and clinical data, then values the generics business using an exit P/E and innovative drugs through a risk-adjusted discounted-cash-flow framework.

Methodology notes

• Valuation methodsP/E and PEG Valuation

  Five-year exit P/E valuation for the generics business

  The report applies a 10x long-term exit P/E to value Hengrui's generics business at Rmb39.3bn.

• Valuation methodsDCF (Discounted Cash Flow)

  Risk-adjusted DCF for innovative drugs

  The report discounts the innovative-drug opportunity using a 9.0% WACC and 3% terminal growth rate, deriving Rmb390.7bn of valuation.

• Industry AnalysisProduct life cycle

  Pipeline-stage and product-differentiation analysis

  The report compares clinical stages, efficacy, tolerability, delivery formats and novel mechanisms to explain Hengrui's positioning in next-generation obesity therapies.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Hengrui Medicine (600276.SS)

  Primary covered company; the Novo license-out is viewed as validation of its obesity pipeline and overseas business-development strategy.

  Strengths

  Diversified next-generation obesity pipeline, Phase II HRS-9531 data, established sales force, and nine recently launched products with sales above Rmb1bn.

  Weaknesses

  Entered the GLP-1 field later than global peers; HRS-1596 remains at a very early stage.

  Comparison

  Novo's willingness to commit US$300mn upfront is presented as validation against a competitive global obesity-therapy landscape.

  Risks

  Slower innovative-drug ramp after NRDL listing, late-stage R&D failures, higher global-expansion expenses, pricing pressure, and weaker license-out progress.

• Novo Nordisk

  Counterparty obtaining exclusive ex-China rights to HRS-1596.

  Strengths

  Described as a global leader in obesity.

  Comparison

  Its commitment is used by the report as external validation of HRS-1596 and differentiated oral incretin therapies.

Key data

• HRS-1596 upfront paymentUS$300mnNovo's upfront payment for exclusive ex-China rights.
• HRS-1596 potential milestonesUp to US$2.3bnDevelopment, regulatory and commercial milestones, in addition to sales royalties.
• HRS-1596 development timingChina Phase I planned in 2026; preliminary data expected in 2027The asset has China IND approval for obesity and type 2 diabetes studies.
• HRS-9531 Phase II weight loss12.1% at week 26; 9.8% placebo-adjustedReported efficacy for Hengrui's strategic GLP-1/GIP asset.
• HRS-9531 vomiting rate11.4%Reported tolerability measure.
• Target price and upsideRmb73.86; 61.9%12-month target price and implied upside versus Rmb45.62 as of 29 September 2026 close.
• Innovative-drug valuationRmb390.7bnRisk-adjusted DCF valuation using 9.0% WACC and 3% terminal growth.
• Generics-business valuationRmb39.3bnBased on a five-year exit P/E of 10x.

Impact & implications

Goldman Sachs believes Novo's commitment strengthens the strategic case for Hengrui's differentiated oral incretin pipeline and supports its overseas business-development narrative. The institution expects innovative drugs, including obesity assets, to become important future growth drivers as the effect of prior volume-based procurement price cuts has largely reset.

Risks

• Innovative drugs may ramp more slowly than expected after NRDL listing.
• Key late-stage R&D programs may fail.
• R&D and administrative expenses for global expansion may exceed expectations.
• Price cuts for generics and innovative drugs may be greater than expected.
• License-out and broader go-global progress may fall below expectations.

What to watch

• Start of HRS-1596 China Phase I trials in 2026 and preliminary data expected in 2027.
• Progress of Novo's development of HRS-1596 outside Greater China.
• Further clinical evidence for HRS-9531 and Hengrui's other differentiated obesity mechanisms.
• Execution of additional overseas licensing and business-development transactions.
• Commercial ramp of innovative drugs following NRDL listing and the extent of drug-price pressure.